MedTrace Logo

Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers

NCT02666833 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2016-09-15

No results posted yet for this study

Summary

The purpose of the study is to evaluate the ability and efficacy of using a polarization-enhanced reflectance and fluorescence imaging device, PERFIS, (see the Device Brochure) for demarcation of nonmelanoma skin cancer margins prior to surgery. PERFIS is a harmless and non-invasive device that has been used to image biological tissue both in vitro and in vivo. In this study it will be used to image nonmelanoma skin cancer lesions prior to surgery. The use of PERFIS will not affect patient care or treatment decisions in any way. No extra tissue will be used for imaging.

Conditions

  • Carcinoma, Basal Cell
  • Carcinoma, Squamous Cell

Interventions

DEVICE

Polarization Enhanced Reflectance and Fluorescence System

Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-07-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02666833 on ClinicalTrials.gov